EP3337474A4 - QUANTITATIVE PERIORBITAL APPLICATION OF OPHTHALMIC MEDICINES - Google Patents

QUANTITATIVE PERIORBITAL APPLICATION OF OPHTHALMIC MEDICINES Download PDF

Info

Publication number
EP3337474A4
EP3337474A4 EP16837713.3A EP16837713A EP3337474A4 EP 3337474 A4 EP3337474 A4 EP 3337474A4 EP 16837713 A EP16837713 A EP 16837713A EP 3337474 A4 EP3337474 A4 EP 3337474A4
Authority
EP
European Patent Office
Prior art keywords
periorbital
quantitative
application
ophthalmic medicines
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16837713.3A
Other languages
German (de)
French (fr)
Other versions
EP3337474A1 (en
Inventor
David Woodward
Weizhen Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenivision Inc
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of EP3337474A1 publication Critical patent/EP3337474A1/en
Publication of EP3337474A4 publication Critical patent/EP3337474A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
EP16837713.3A 2015-08-19 2016-08-17 QUANTITATIVE PERIORBITAL APPLICATION OF OPHTHALMIC MEDICINES Withdrawn EP3337474A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (2)

Publication Number Publication Date
EP3337474A1 EP3337474A1 (en) 2018-06-27
EP3337474A4 true EP3337474A4 (en) 2019-04-10

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16837713.3A Withdrawn EP3337474A4 (en) 2015-08-19 2016-08-17 QUANTITATIVE PERIORBITAL APPLICATION OF OPHTHALMIC MEDICINES

Country Status (9)

Country Link
US (1) US9820954B2 (en)
EP (1) EP3337474A4 (en)
JP (1) JP6924429B2 (en)
KR (1) KR102685479B1 (en)
CN (1) CN108135873A (en)
AU (1) AU2016308105B2 (en)
CA (1) CA2992483C (en)
MX (1) MX391627B (en)
WO (1) WO2017031137A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
WO2019005139A1 (en) * 2017-06-30 2019-01-03 Jenivision Inc. Formulations for hair growth
GB2597731A (en) * 2020-07-31 2022-02-09 Imperial College Innovations Ltd Preterm labour
KR20230142749A (en) * 2021-02-05 2023-10-11 제니비젼 인크. Compositions and methods for periorbital administration of EP2 receptor agonists
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN116869991A (en) * 2023-06-06 2023-10-13 南昌大学 Use of Naringenin in the preparation of medicaments for the treatment and/or prevention of eye diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098458A2 (en) * 2008-02-05 2009-08-13 Asterand Uk Limited Biaryl amides
WO2010111449A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
DE3851152T2 (en) 1987-09-03 1995-01-26 Univ Georgia CYCLOSPORINE EYE PRODUCTS.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
WO2005102058A2 (en) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
BRPI0606172A2 (en) * 2005-06-08 2009-06-02 Targegen Inc methods and compositions for treating eye disorders
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
KR20090042956A (en) * 2006-08-28 2009-05-04 센주 세이야꾸 가부시키가이샤 Ophthalmic percutaneous absorption type preparation
JP2010508306A (en) * 2006-10-31 2010-03-18 アルコン リサーチ， リミテッド PAI-1 binding modulators for treating eye disorders
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
BRPI0819105A2 (en) 2007-11-08 2019-09-24 Aciex Therapeutics Inc composition for the treatment and prevention of eyelid edema
ES2752008T3 (en) 2009-10-30 2020-04-02 Intratus Inc Methods and compositions for sustained drug release
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
WO2011112713A2 (en) 2010-03-09 2011-09-15 Toxcure, Inc. Microneedle nasal delivery device
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
CN103930396B (en) * 2011-09-16 2016-11-16 赛诺菲 Anil, its preparation and treatment use thereof
CN104039309B (en) 2011-11-15 2018-03-06 阿勒根公司 Sustained-acting formulations of cyclosporine form 2
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (en) 2012-12-14 2014-01-08 上海市第七人民医院 Micro-needle roller device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098458A2 (en) * 2008-02-05 2009-08-13 Asterand Uk Limited Biaryl amides
WO2010111449A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANON: "Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use", 9 October 2017 (2017-10-09), XP055918401, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/benzalkonium-chloride> [retrieved on 20220505] *
RASMUSSEN CAROL A. ET AL: "Benzalkonium Chloride and Glaucoma", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 30, no. 2-3, 1 March 2014 (2014-03-01), US, pages 163 - 169, XP055918403, ISSN: 1080-7683, DOI: 10.1089/jop.2013.0174 *
ROSIN LAUREN; BELL NICHOLAS ET AL: "Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops", CLINICAL OPHTHALMOLOGY, 1 October 2013 (2013-10-01), pages 2131, XP055918404, DOI: 10.2147/OPTH.S41358 *
See also references of WO2017031137A1 *
WOODWARD DAVID F. ET AL: "A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 35, no. 5, 1 June 2019 (2019-06-01), US, pages 265 - 277, XP055918389, ISSN: 1080-7683, DOI: 10.1089/jop.2018.0126 *
WOODWARD DAVID F. ET AL: "Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 36, no. 8, 1 October 2020 (2020-10-01), US, pages 636 - 648, XP055918248, ISSN: 1080-7683, DOI: 10.1089/jop.2020.0033 *

Also Published As

Publication number Publication date
CA2992483A1 (en) 2017-02-23
KR20180042348A (en) 2018-04-25
CA2992483C (en) 2024-03-19
MX391627B (en) 2025-03-21
JP2018528169A (en) 2018-09-27
JP6924429B2 (en) 2021-08-25
EP3337474A1 (en) 2018-06-27
AU2016308105A1 (en) 2018-02-15
AU2016308105B2 (en) 2021-05-27
MX2018001918A (en) 2018-11-09
CN108135873A (en) 2018-06-08
WO2017031137A1 (en) 2017-02-23
KR102685479B1 (en) 2024-07-15
US20170049734A1 (en) 2017-02-23
US9820954B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
DK3448999T3 (en) OLIGONUCLEOTIDES FOR TREATMENT OF EYE DISEASE
DK3331876T3 (en) MODULATORS OF ROR-GAMMA
DK3212233T3 (en) COMBINATION THERAPY FOR TREATMENT OF DISEASE
BR112016027906A2 (en) fail-safe operation of eye mountable device
DK3240612T3 (en) PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
MA41997A (en) COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES
HUE056287T2 (en) Treatment of pancreatitis
EP3360010A4 (en) ACCORDABLE SOURCE OF BI-PHOTONS
EP3406336A4 (en) NANOFEUILLE OF TYPE STRUCTURE C UR-ECORCE
EP3337474A4 (en) QUANTITATIVE PERIORBITAL APPLICATION OF OPHTHALMIC MEDICINES
IL263050B (en) History of Subtirum
DK3097085T3 (en) BENZOXAZINE DERIVATIVES FOR THE TREATMENT OF SKIN DISEASES
LT3685847T (en) MODULATORS OF COMPLEMENT ACTIVITY
EP3381018A4 (en) REGIONS OF TRIGGING
HUE053443T2 (en) Heteroaryl compounds for the treatment of eye diseases
HUE056613T2 (en) Modulators of complement activity
DK3283210T3 (en) COURSE OF ACTION
LT3119384T (en) TREATMENT OF INTRAHEPATIC CHOLESTAIN DISEASES
DK3164394T3 (en) GLS1 INHIBITORS FOR TREATMENT OF DISEASES
IL257764B (en) Methods of treating diseases
EP3277701A4 (en) SYNTHESIS OF DESOSAMINES
HUE053974T2 (en) Ophthalmic medicinal product
HUE065920T2 (en) Reference dosing of caps
EP3446199A4 (en) MODIFICATION OF CONTEXT OF REQUESTS
PT3384052T (en) CLINICAL CORRELATES OF IMMUNOTHERAPY EFFECTIVENESS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180312

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190314

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20190307BHEP

Ipc: A61P 27/02 20060101ALI20190307BHEP

Ipc: A61K 31/196 20060101AFI20190307BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201123

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JENIVISION INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250613